These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3032491)

  • 1. Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.
    Rakhit A; Kochak GM; Tipnis V; Hurley ME
    Clin Pharmacol Ther; 1987 May; 41(5):580-6. PubMed ID: 3032491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of pentopril, a new angiotensin-converting-enzyme inhibitor in humans.
    Rakhit A; Hurley ME; Tipnis V; Coleman J; Rommel A; Brunner HR
    J Clin Pharmacol; 1986 Mar; 26(3):156-64. PubMed ID: 3007583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renal impairment on disposition of pentopril and its active metabolite.
    Rakhit A; Radensky P; Szerlip HM; Kochak GM; Audet PR; Hurley ME; Feldman GM
    Clin Pharmacol Ther; 1988 Jul; 44(1):39-48. PubMed ID: 3391004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentopril-cimetidine interaction caused by a reduction in hepatic blood flow.
    Kochak GM; Rakhit A; Thompson TN; Hurley ME
    J Clin Pharmacol; 1988 Mar; 28(3):222-7. PubMed ID: 3360970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of pentopril, a new orally active angiotensin-converting enzyme inhibitor, and its active metabolite in rats.
    Rakhit A; Kochak G; Dotson R; Tipnis V
    J Pharm Sci; 1985 Sep; 74(9):947-52. PubMed ID: 2999376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of pentopril in the elderly.
    Rakhit A; Kochak GM; Tipnis V; Radensky P; Hurley ME; Williams R
    Br J Clin Pharmacol; 1987 Sep; 24(3):351-7. PubMed ID: 2822067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the bioavailability of pentopril, an angiotensin-converting-enzyme inhibitor, in healthy subjects.
    Rakhit A; Hurley ME; Redalieu E; Kochak G; Tipnis V; Coleman J; Rommel A
    J Clin Pharmacol; 1985 Sep; 25(6):424-8. PubMed ID: 2997306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary evaluation of furosemide-probenecid interaction in humans.
    Smith DE; Gee WL; Brater DC; Lin ET; Benet LZ
    J Pharm Sci; 1980 May; 69(5):571-5. PubMed ID: 7381747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers.
    De Lepeleire I; Van Hecken A; Verbesselt R; Kaiser G; Barner A; Holmes I; De Schepper PJ
    Eur J Clin Pharmacol; 1988; 34(5):465-8. PubMed ID: 3203706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin-converting enzyme inhibition on renal adaptations to acute furosemide administration in conscious rats.
    Bak M; Shalmi M; Petersen JS; Poulsen LB; Christensen S
    J Pharmacol Exp Ther; 1993 Jul; 266(1):33-40. PubMed ID: 8392557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.
    Homeida M; Roberts C; Branch RA
    Clin Pharmacol Ther; 1977 Oct; 22(4):402-9. PubMed ID: 902453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of probenecid on furosemide kinetics and natriuresis in man.
    Honari J; Blair AD; Cutler RE
    Clin Pharmacol Ther; 1977 Oct; 22(4):395-401. PubMed ID: 902452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.
    Smith DE; Lin ET; Benet LZ
    Drug Metab Dispos; 1980; 8(5):337-42. PubMed ID: 6107232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of organ perfusion on renal drug transport. Application to furosemide in the isolated perfused rat kidney.
    Lee LJ; Smith DE
    Drug Metab Dispos; 1989; 17(1):32-6. PubMed ID: 2566466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats.
    Nagai N; Ogata H
    J Pharm Sci; 1996 Jul; 85(7):720-4. PubMed ID: 8818996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of reduced effects of loop diuretics in healthy volunteers and in patients with renal disease.
    Sjöström P
    Scand J Urol Nephrol Suppl; 1988; 111():1-66. PubMed ID: 3201162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of indomethacin on the pharmacokinetics, diuretic response and hemodynamics of furosemide in the dog.
    Data JL; Rane A; Gerkens J; Wilkinson GR; Nies AS; Branch RA
    J Pharmacol Exp Ther; 1978 Aug; 206(2):431-8. PubMed ID: 682123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans.
    Vree TB; van der Ven AJ
    J Pharm Pharmacol; 1999 Mar; 51(3):239-48. PubMed ID: 10344623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man.
    MacDonald TM; Craig K; Watson ML
    Br J Clin Pharmacol; 1989 Dec; 28(6):683-94. PubMed ID: 2532921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man.
    Marone C; Muggli F; Lahn W; Frey FJ
    Eur J Clin Invest; 1985 Oct; 15(5):253-7. PubMed ID: 3935455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.